Publication
Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Yuko Shirouchi, Yuko Mishima, Suguru Fukuhara, Shinichi Makita, Koji Izutsu, Yasuhito Terui, Takuro Suzuki, Atsuko Kawasaki, Takeshi Miyake, Dai Maruyama
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Glofitamab is a T-cell engaging CD20xCD3 bispecific antibody approved for treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in the US and Europe. METHODS: This phase I study (jRCT2080225077) investigated safety, pharmacokinetics, and efficacy of glofitamab in…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 2
- cancerHodgkin Lymphomadictionary0.60
- cancerNon-Hodgkin Lymphomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available